This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: Novartis Weighs Sale or Spinoff of Generic Drug Unit Sandoz
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Business > Novartis Weighs Sale or Spinoff of Generic Drug Unit Sandoz
Business

Novartis Weighs Sale or Spinoff of Generic Drug Unit Sandoz

Editorial Board Published October 26, 2021
Share
Novartis Weighs Sale or Spinoff of Generic Drug Unit Sandoz
SHARE

Novartis AG NVS -1.84% said it is considering the sale or spinoff of its generic drugs business Sandoz, a move that would focus the once-sprawling healthcare conglomerate solely on innovative prescription drugs.

Sandoz, like many generic drugmakers, has struggled with falling prices in the U.S. in recent years. Generic drugs are lower-cost versions of prescription medicines whose patents have expired. While their prices are usually far below those of the branded drugs that they imitate, increased competition has driven those prices even lower in recent years.

In response to greater competition, Novartis has pivoted Sandoz toward higher-value generics, such as biosimilars, which are near-replicas of biologic drugs made using living cells. Sandoz has also become an autonomous unit within Novartis, to give it more flexibility. But the unit, which accounts for around a fifth of total sales for Novartis, has still proven a drag on the company’s growth. In the third quarter, Sandoz sales fell 2% at constant currencies to $2.4 billion despite volumes increasing. Sandoz’s U.S. sales dropped 20%.

Novartis shares were up 0.9% in early trading.

Chief Executive Vas Narasimhan said Tuesday it was the right moment to review Sandoz’s strategic fit within Novartis. The company said it had launched a strategic review of Sandoz that would consider all options, from retaining the business to separating it. Dr. Narasimhan said he expects to complete the review by the end of next year.

Wimal Kapadia, analyst at Bernstein, said in a note that while Sandoz was a reliable cash-generator for Novartis, the unit would be more profitable, and probably generate higher returns on capital, if it were to be sold or spun out into a stand-alone business.

A separation of Sandoz would be the final step toward Novartis focusing solely on innovative drugs. Over the last decade, it has shed units that sold animal medicines, vaccines, drugstore staples, contact lenses and tools for eye surgery.

Since taking the helm in early 2018, Dr. Narasimhan has doubled down on innovative medicines and cutting-edge technologies such as gene therapies and radiopharmaceuticals, drugs that carry radioactive particles to tumors for close-range radiotherapy. He also placed a big bet on cholesterol-lowering drug inclisiran, which Novartis acquired around two years ago through a $9.7 billion deal for The Medicines Company. Inclisiran is currently under review with the Food and Drug Administration with a decision expected early next year.

The announcement of the Sandoz review came as Novartis reported that third-quarter sales increased 5% at constant currencies to $13.03 billion, driven by strong sales of some of its prescription drugs. Operating income rose 32% to $3.23 billion.

Novartis also boosted its long-term sales expectations for its two top-selling drugs, Entresto for heart failure and Cosentyx for various immunological conditions. It now expects Cosentyx to generate revenue of at least $7 billion a year at its peak, up from earlier guidance of $5 billion. It expects Entresto to make at least $5 billion a year at its peak, up from $4 billion previously.

Write to Denise Roland at [email protected]

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

TAGGED:Business NewsPAIDWall Street Publication
Share This Article
Twitter Email Copy Link Print
Previous Article UBS Earnings Driven Higher by Fees From Wealthy Clients UBS Earnings Driven Higher by Fees From Wealthy Clients
Next Article ‘Bad Bets,’ Episode 3 ‘Bad Bets,’ Episode 3

Editor's Pick

Mandy Moore ‘Unrecognizable’ to Followers After Debuting New Face

Mandy Moore ‘Unrecognizable’ to Followers After Debuting New Face

Studying Time: 4 minutes Mandy Moore has followers scratching their heads. This isn’t about her GoFundMe controversy earlier this 12…

By Editorial Board 6 Min Read
Katy Perry & Justin Trudeau Pack on PDA within the Pacific
Katy Perry & Justin Trudeau Pack on PDA within the Pacific

Studying Time: 3 minutes Katy Perry and Justin Trudeau appear to be…

6 Min Read
Inside the ,890 Carolina Herrera Gown Scandal: Hollywood Hills Wife Exposes
Inside the $4,890 Carolina Herrera Gown Scandal: Hollywood Hills Wife Exposes

From a distance, the $4,890 Carolina Herrera gown glimmers like old money…

5 Min Read

Oponion

High prospect Eldridge held hitless in debut as SF Giants lose third straight

High prospect Eldridge held hitless in debut as SF Giants lose third straight

PHOENIX — Taylor Rashi thought Bryce Eldridge received one. Within…

September 16, 2025

Pill Intended to Be Covid-19’s Tamiflu Succeeds in Key Study

Merck MRK 0.03% & Co. and…

October 1, 2021

Broadcom to Buy VMware for $61 Billion

Broadcom Chief Executive Hock Tan’s $61…

May 26, 2022

Google’s Newest AI Ransomware Protection Solely Goes So Far

Ransomware assaults have loomed for years…

September 30, 2025

INDIA Bloc To Maintain First Meet Since 2024 Polls As we speak: Who’ll Attend, Who’ll Skip After AAP’s Exit? | Politics Information

Final Up to date:July 19, 2025,…

July 19, 2025

You Might Also Like

FundRelis Restora Brings Accountability to the Wild West of Online Scams
BusinessTrending

FundRelis Restora Brings Accountability to the Wild West of Online Scams

Zurich, Switzerland — In a financial era defined by digital innovation and unregulated trading, a quiet revolution is taking shape inside…

5 Min Read
Russia for Business: Experts Who Help Drive Decisions
BusinessTrending

Russia for Business: Experts Who Help Drive Decisions

Amid sanctions and the restructuring of global supply chains, understanding the logic behind Russia’s actions has become a practical necessity…

4 Min Read
The Quiet Shift in America’s Workforce: Why Side Hustles Are Becoming Essential for Women Over 40
BusinessTrending

The Quiet Shift in America’s Workforce: Why Side Hustles Are Becoming Essential for Women Over 40

Across the nation, a quiet but powerful workforce shift is underway. Increasingly, women over 40 are seeking side hustles to…

4 Min Read
Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution
Business

Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution

At a time when billions of linked objects are reshaping industries, Thales has achieved a vital safety certification for its…

4 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?